As discussed before, KRAS, a commonly mutated proto‐oncogene, could be detected in several human malignancies.[88] Previous studies showed that KRAS variants such as G12D and G12V are present in 20% to 30% of CRCs.[77, 89, 90, 91, 92, 93] An investigation has shown that HLA‐C*08:02‐restricted TIL‐based immunotherapy targeting KRASG12D oncogene mutation could reduce tumor development in metastatic CRC.[18] Metastasis to lung regressed following infusion of 1.11 × 1011 HLA‐C*08:02–restricted KRASG12D targeting TILs. The gene discussed is KRAS; the disease is neoplasm.